B7-33
Also known as: Relaxin Single-Chain Peptide, B-Chain Relaxin Analog
A single-chain relaxin analog with potent anti-fibrotic and cardiovascular benefits.
Overview
B7-33 is a simplified, single-chain version of the relaxin-2 hormone B-chain. It retains the anti-fibrotic and cardioprotective properties of relaxin but with improved stability and easier synthesis. It shows promise for heart failure, fibrosis, and vascular conditions.
Mechanism of Action
Activates RXFP1 (relaxin family peptide receptor 1). Stimulates nitric oxide production, inhibits TGF-β signaling, reduces collagen deposition, and promotes vasodilation. Anti-inflammatory effects via multiple pathways.
Pharmacokinetics
Improved stability over native relaxin. Half-life ~hours. Subcutaneous administration.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Research Protocol
0.5-2 mg
Daily
2-4 weeks
Experimental dosing
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Reduced cardiac fibrosis in animal models
- 2Improved cardiac function in heart failure
- 3Anti-fibrotic effects comparable to serelaxin
- 4Enhanced stability vs native relaxin
Side Effects & Contraindications
Reported Side Effects
- Hypotension
- Headache
- Flushing
Contraindications
- Hypotension
- Pregnancy (research status)
Safety Considerations
May cause hypotension. Monitor blood pressure. Research compound status.
Storage Requirements
Refrigerate 2-8°C
Scientific References
- 1